Identification of the Impact of Acute Pancreatitis on Quality of Life
- Conditions
- Quality of LifeAcute Pancreatitis
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04222075
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
cfDNA in Diagnosis and Differential Diagnosis of Ovarian Endometriosis
- Conditions
- Circulating Free DNA
- Interventions
- Diagnostic Test: DNA extraction and methylation detection
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 390
- Registration Number
- NCT04220710
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 211
- Registration Number
- NCT04217967
- Locations
- 🇨🇳
PekingUMCH, Beijing, Beijing, China
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT04217798
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
RCT for SSLF vs. ISFF With Conventional Surgical Instruments in Chinese Apical Prolapse Female Patients
Not Applicable
Recruiting
- Conditions
- Apical Prolapse
- Interventions
- Procedure: native tissue repair procedures with conventional surgical instruments
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 320
- Registration Number
- NCT04213027
- Locations
- 🇨🇳
2nd Affiliated hospital of Anhui Medical college, Hefei, Anhui, China
🇨🇳1st Affiliated hospital of PLA general hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Phase 2
Recruiting
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT04211168
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, Beijing, China
Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04188249
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study About Nutritional Support of Enhanced Protein in Critical Patients
Not Applicable
- Conditions
- Critical Illness
- Interventions
- Dietary Supplement: a production consist of various oligopeptides and the whey proteinDietary Supplement: maltodextrinDietary Supplement: basic energy intake
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT04177446
SinTilimab After Radiation (STAR Study)
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT04167657
- Locations
- 🇨🇳
Department of Respiratory Medicine, Peking Union Medical College Hospita, Beijing, Beijing, China
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
Phase 2
- Conditions
- NSCLC
- Interventions
- Drug: Anlotinib, oral capsuleBiological: Pembrolizumab
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT04164745
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath